Patent

1. A compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein

denotes a single or double bond;

R 1 is cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted, branched or unbranched arylalkyl; or substituted or unsubstituted, branched or unbranched heteroarylalkyl;

R 2 and R 3 are independently cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; substituted or unsubstituted, branched or unbranched arylalkyl; substituted or unsubstituted, branched or unbranched heteroarylalkyl; —C(═O)R B ; —SOR B ; —SO 2 R B ; or —C(R B ) 3 ; wherein each occurrence of R B is independently hydrogen; halogen; a protecting group; aliphatic; heteroaliphatic; acyl; aryl; heteroaryl; hydroxyl; alkoxy; aryloxy; amino; alkylamino; dialkylamino; or heteroaryloxy; or

R 2 and R 3 may optionally be taken together with the intervening nitrogen to form a saturated or unsaturated, substituted or unsubstituted heterocyclic moiety;

R 4 is hydrogen, C 1-6 aliphatic, or a protecting group;

R 5 is hydrogen, C 1-6 aliphatic, or a protecting group;

R 6 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR F ; —C(═O)R F ; —CO 2 R F ; —C(═O)N(R F ) 2 ; —CN; —SCN; —SR F ; —SOR F ; —SO 2 R F ; —NO 2 ; —N(R F ) 2 ; —NHC(O)R F ; or —C(R F ) 3 ; wherein each occurrence of R F is independently hydrogen; halogen; a protecting group; aliphatic; heteroaliphatic; acyl; aryl moiety; heteroaryl; hydroxy; alkoxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy; or heteroarylthioxy; and

n is 0, 1, 2, or 3; wherein the compound of formula (I) is not one of the following:

2. The compound of claim 1 , wherein the compound has the stereochemistry of formula (Ia):

3. The compound of claim 1 , wherein the compound has the stereochemistry of formula (Ib):

4. The compound of claim 1 of formula:

5. The compound of claim 1 of formula:

6. The compound of claim 1 of formula:

7. The compound of claim 1 of formula:

8. The compound of claim 1 of formula:

wherein

R A is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR; —C(═O)R; —CO 2 R; —C(═O)N(R) 2 ; —CN; —SCN; —SR; —SOR; —SO 2 R; —NO 2 ; —N(R) 2 ; —NHC(O)R; or —C(R) 3 ; wherein each occurrence of R is independently hydrogen; halogen; a protecting group; aliphatic; heteroaliphatic; acyl; aryl moiety; heteroaryl; alkoxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy; or heteroarylthioxy; and

m is 0-5, inclusive.

9. The compound of claim 1 , wherein R 2 and R 3 are taken together to form a heterocyclic ring.

10. The compound of claim 1 , wherein each of R 2 and R 3 is C 1-6 alkyl, C 1-6 heteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl.

11. The compound of claim 1 , wherein one of R 2 and R 3 is C 1-6 alkyl, C 1-6 heteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl.

12. A compound having the formula:

13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 ; and a pharmaceutically acceptable excipient.

14. A method for treating an OGT-associated disease or condition in a subject comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1 .

15. The method of claim 14 , wherein the subject is human.

16. The method of claim 14 , wherein the OGT-associated disease or condition is cancer, diabetes mellitus type I, diabetes mellitus type II, insulin resistance, a complication of diabetes, or inflammatory disease.

17. The compound of claim 1 , wherein is a single bond and R 1 is not phenyl or benzyl.

18. The compound of claim 1 , wherein is a double bond.

19. The compound of claim 1 of formula:

20. The compound of claim 1 of formula:

21. The compound of claim 20 of formula:

22. The compound of claim 20 of formula:

23. The compound of claim 7 , wherein the compound has the stereochemistry of formula:

24. The compound of claim 7 , wherein the compound has the stereochemistry of formula:

25. The compound of claim 8 , wherein the compound has the stereochemistry of formula:

26. The compound of claim 8 , wherein the compound has the stereochemistry of formula:

27. The compound of claim 8 , wherein R A is halogen and m is 1.

28. The compound of claim 8 , wherein R A is chloro or fluoro.

29. The compound of claim 9 , wherein R 2 and R 3 are taken together to form a 6-membered heterocyclic ring.

30. The compound of claim 9 , wherein R 2 and R 3 are taken together to form an optionally substituted pyrrolidine, piperidine, or homopiperidine ring.

31. The compound of claim 9 , wherein R 2 and R 3 are taken together to form an optionally substituted piperazine ring.

32. The compound of claim 31 , wherein the piperazine ring is substituted with an optionally substituted aryl or heteroaryl moiety.

33. The compound of claim 1 , wherein at least one of R 2 and R 3 is aryl, arylalkyl, heteroaryl, or heteroarylalkyl.

34. The compound of claim 33 , wherein each of R 2 and R 3 is arylalkyl or heteroarylalkyl.

35. The compound of claim 33 , wherein each of R 2 and R 3 is heteroarylalkyl.

36. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 12 ; and a pharmaceutically acceptable excipient.

37. The pharmaceutical composition of claim 13 , administered in an amount sufficient to deliver about 0.001 mg/kg to about 100 mg/kg of subject body weight per day.